Shelling out $5B+, PerkinElmer pays the big bucks for antibody and reagent player
PerkinElmer has been busy on the acquisition front throughout the Covid-19 pandemic, and on Monday, the Massachusetts-based diagnostics and life sciences company added the biggest feather to its cap.
PerkinElmer will acquire antibody and reagents provider BioLegend for nearly $5.25 billion, the entities announced Monday morning. The deal is PerkinElmer’s third acquisition since November 2020 as it kicked development of Covid-19 testing into high gear, as well as the company’s biggest buyout ever.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.